APOE4 impairs the microglial response in Alzheimer's disease by inducing TGFβ-mediated checkpoints.


Journal

Nature immunology
ISSN: 1529-2916
Titre abrégé: Nat Immunol
Pays: United States
ID NLM: 100941354

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 03 11 2022
accepted: 15 08 2023
medline: 30 10 2023
pubmed: 26 9 2023
entrez: 25 9 2023
Statut: ppublish

Résumé

The APOE4 allele is the strongest genetic risk factor for late-onset Alzheimer's disease (AD). The contribution of microglial APOE4 to AD pathogenesis is unknown, although APOE has the most enriched gene expression in neurodegenerative microglia (MGnD). Here, we show in mice and humans a negative role of microglial APOE4 in the induction of the MGnD response to neurodegeneration. Deletion of microglial APOE4 restores the MGnD phenotype associated with neuroprotection in P301S tau transgenic mice and decreases pathology in APP/PS1 mice. MGnD-astrocyte cross-talk associated with β-amyloid (Aβ) plaque encapsulation and clearance are mediated via LGALS3 signaling following microglial APOE4 deletion. In the brains of AD donors carrying the APOE4 allele, we found a sex-dependent reciprocal induction of AD risk factors associated with suppression of MGnD genes in females, including LGALS3, compared to individuals homozygous for the APOE3 allele. Mechanistically, APOE4-mediated induction of ITGB8-transforming growth factor-β (TGFβ) signaling impairs the MGnD response via upregulation of microglial homeostatic checkpoints, including Inpp5d, in mice. Deletion of Inpp5d in microglia restores MGnD-astrocyte cross-talk and facilitates plaque clearance in APP/PS1 mice. We identify the microglial APOE4-ITGB8-TGFβ pathway as a negative regulator of microglial response to AD pathology, and restoring the MGnD phenotype via blocking ITGB8-TGFβ signaling provides a promising therapeutic intervention for AD.

Identifiants

pubmed: 37749326
doi: 10.1038/s41590-023-01627-6
pii: 10.1038/s41590-023-01627-6
doi:

Substances chimiques

Apolipoprotein E4 0
Galectin 3 0
Amyloid beta-Peptides 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1839-1853

Subventions

Organisme : NIA NIH HHS
ID : R01 AG054672
Pays : United States
Organisme : Alzheimer's Association
ID : AARF-21-846786
Pays : United States
Organisme : NEI NIH HHS
ID : K08 EY030160
Pays : United States

Informations de copyright

© 2023. The Author(s), under exclusive licence to Springer Nature America, Inc.

Références

Jansen, I. E. et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk. Nat. Genet. 51, 404–413 (2019).
pubmed: 30617256 pmcid: 6836675 doi: 10.1038/s41588-018-0311-9
Wightman, D. P. et al. A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer’s disease. Nat. Genet. 53, 1276–1282 (2021).
pubmed: 34493870 pmcid: 10243600 doi: 10.1038/s41588-021-00921-z
Nott, A. et al. Brain cell type-specific enhancer–promoter interactome maps and disease-risk association. Science 366, 1134–1139 (2019).
pubmed: 31727856 pmcid: 7028213 doi: 10.1126/science.aay0793
Krasemann, S. et al. The TREM2–APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity 47, 566–581 (2017).
pubmed: 28930663 pmcid: 5719893 doi: 10.1016/j.immuni.2017.08.008
Keren-Shaul, H. et al. A unique microglia type associated with restricting development of Alzheimer’s disease. Cell 169, 1276–1290 (2017).
pubmed: 28602351 doi: 10.1016/j.cell.2017.05.018
Farrer, L. A. et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278, 1349–1356 (1997).
pubmed: 9343467 doi: 10.1001/jama.1997.03550160069041
Corder, E. H. et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261, 921–923 (1993).
pubmed: 8346443 doi: 10.1126/science.8346443
Strittmatter, W. J. et al. Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl Acad. Sci. USA 90, 1977–1981 (1993).
pubmed: 8446617 pmcid: 46003 doi: 10.1073/pnas.90.5.1977
Raber, J. et al. Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females. Proc. Natl Acad. Sci. USA 95, 10914–10919 (1998).
pubmed: 9724804 pmcid: 27995 doi: 10.1073/pnas.95.18.10914
Youmans, K. L. et al. APOE4-specific changes in Aβ accumulation in a new transgenic mouse model of Alzheimer disease. J. Biol. Chem. 287, 41774–41786 (2012).
pubmed: 23060451 pmcid: 3516726 doi: 10.1074/jbc.M112.407957
Liu, D. S. et al. APOE4 enhances age-dependent decline in cognitive function by down-regulating an NMDA receptor pathway in EFAD-Tg mice. Mol. Neurodegener. 10, 7 (2015).
pubmed: 25871877 pmcid: 4391134 doi: 10.1186/s13024-015-0002-2
Wang, C. et al. Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia. Neuron 109, 1657–1674 (2021).
pubmed: 33831349 pmcid: 8141024 doi: 10.1016/j.neuron.2021.03.024
Butovsky, O. et al. Identification of a unique TGF-β-dependent molecular and functional signature in microglia. Nat. Neurosci. 17, 131–143 (2014).
pubmed: 24316888 doi: 10.1038/nn.3599
Margeta, M. A. et al. Apolipoprotein E4 impairs the response of neurodegenerative retinal microglia and prevents neuronal loss in glaucoma. Immunity 55, 1627–1644 (2022).
Parkhurst, C. N. et al. Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. Cell 155, 1596–1609 (2013).
pubmed: 24360280 pmcid: 4033691 doi: 10.1016/j.cell.2013.11.030
Goldmann, T. et al. Origin, fate and dynamics of macrophages at central nervous system interfaces. Nat. Immunol. 17, 797–805 (2016).
pubmed: 27135602 pmcid: 4968048 doi: 10.1038/ni.3423
Cugurra, A. et al. Skull and vertebral bone marrow are myeloid cell reservoirs for the meninges and CNS parenchyma. Science 373, eabf7844 (2021).
pubmed: 34083447 pmcid: 8863069 doi: 10.1126/science.abf7844
Gosselin, D. et al. Environment drives selection and function of enhancers controlling tissue-specific macrophage identities. Cell 159, 1327–1340 (2014).
pubmed: 25480297 pmcid: 4364385 doi: 10.1016/j.cell.2014.11.023
Huang, K. L. et al. A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer’s disease. Nat. Neurosci. 20, 1052–1061 (2017).
pubmed: 28628103 pmcid: 5759334 doi: 10.1038/nn.4587
Serrano-Pozo, A., Frosch, M. P., Masliah, E. & Hyman, B. T. Neuropathological alterations in Alzheimer disease. Cold Spring Harb. Perspect. Med. 1, a006189 (2011).
pubmed: 22229116 pmcid: 3234452 doi: 10.1101/cshperspect.a006189
Shi, Y. et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 549, 523–527 (2017).
pubmed: 28959956 pmcid: 5641217 doi: 10.1038/nature24016
Yoshiyama, Y. et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337–351 (2007).
pubmed: 17270732 doi: 10.1016/j.neuron.2007.01.010
Rosenzweig, N. et al. PD-1/PD-L1 checkpoint blockade harnesses monocyte-derived macrophages to combat cognitive impairment in a tauopathy mouse model. Nat. Commun. 10, 465 (2019).
pubmed: 30692527 pmcid: 6349941 doi: 10.1038/s41467-019-08352-5
Radde, R. et al. Aβ
pubmed: 16906128 pmcid: 1559665 doi: 10.1038/sj.embor.7400784
Bennett, F. C. et al. A combination of ontogeny and CNS environment establishes microglial identity. Neuron 98, 1170–1183 (2018).
pubmed: 29861285 pmcid: 6023731 doi: 10.1016/j.neuron.2018.05.014
Van Hove, H. et al. A single-cell atlas of mouse brain macrophages reveals unique transcriptional identities shaped by ontogeny and tissue environment. Nat. Neurosci. 22, 1021–1035 (2019).
pubmed: 31061494 doi: 10.1038/s41593-019-0393-4
Mrdjen, D. et al. High-dimensional single-cell mapping of central nervous system immune cells reveals distinct myeloid subsets in health, aging, and disease. Immunity 48, 380–395 (2018).
pubmed: 29426702 doi: 10.1016/j.immuni.2018.01.011
Jordao, M. J. C. et al. Single-cell profiling identifies myeloid cell subsets with distinct fates during neuroinflammation. Science 363, eaat7554 (2019).
pubmed: 30679343 doi: 10.1126/science.aat7554
Habib, N. et al. Disease-associated astrocytes in Alzheimer’s disease and aging. Nat. Neurosci. 23, 701–706 (2020).
pubmed: 32341542 pmcid: 9262034 doi: 10.1038/s41593-020-0624-8
Munger, J. S. & Sheppard, D. Cross talk among TGF-β signaling pathways, integrins, and the extracellular matrix. Cold Spring Harb. Perspect. Biol. 3, a005017 (2011).
pubmed: 21900405 pmcid: 3220354 doi: 10.1101/cshperspect.a005017
Arnold, T. D. et al. Impaired α
pubmed: 30846482 pmcid: 6446869 doi: 10.1084/jem.20181290
Wolf, Y., Anderson, A. C. & Kuchroo, V. K. TIM3 comes of age as an inhibitory receptor. Nat. Rev. Immunol. 20, 173–185 (2020).
pubmed: 31676858 doi: 10.1038/s41577-019-0224-6
Nakao, A. et al. TGF-β receptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO J. 16, 5353–5362 (1997).
pubmed: 9311995 pmcid: 1170167 doi: 10.1093/emboj/16.17.5353
Olah, M. et al. Single cell RNA sequencing of human microglia uncovers a subset associated with Alzheimer’s disease. Nat. Commun. 11, 6129 (2020).
pubmed: 33257666 pmcid: 7704703 doi: 10.1038/s41467-020-19737-2
Zhou, Y. et al. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease. Nat. Med. 26, 131–142 (2020).
pubmed: 31932797 pmcid: 6980793 doi: 10.1038/s41591-019-0695-9
Travis, M. A. et al. Loss of integrin α
pubmed: 17694047 pmcid: 2670239 doi: 10.1038/nature06110
Nakawesi, J. et al. α
pubmed: 32161355 doi: 10.1038/s41385-020-0276-8
Zhang, Y. et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J. Neurosci. 34, 11929–11947 (2014).
pubmed: 25186741 pmcid: 4152602 doi: 10.1523/JNEUROSCI.1860-14.2014
Liu, Z. et al. Fate mapping via Ms4a3-expression history traces monocyte-derived cells. Cell 178, 1509–1525 (2019).
pubmed: 31491389 doi: 10.1016/j.cell.2019.08.009
Wong, K. et al. Mice deficient in NRROS show abnormal microglial development and neurological disorders. Nat. Immunol. 18, 633–641 (2017).
pubmed: 28459434 doi: 10.1038/ni.3743
Samuels, J. D. et al. The Alzheimer’s disease risk factor INPP5D restricts neuroprotective microglial responses in amyloid β-mediated pathology. Alzheimer’s Dement. https://doi.org/10.1002/alz.13089 (2023).
Iguchi, A. et al. INPP5D modulates TREM2 loss-of-function phenotypes in a β-amyloidosis mouse model. iScience 26, 106375 (2023).
pubmed: 37035000 pmcid: 10074152 doi: 10.1016/j.isci.2023.106375
Dodagatta-Marri, E. et al. Integrin α
pubmed: 34233193 pmcid: 8321414 doi: 10.1016/j.celrep.2021.109309
Mahan, T. E. et al. Selective reduction of astrocyte ApoE3 and ApoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis. Mol. Neurodegener. 17, 13 (2022).
pubmed: 35109920 pmcid: 8811969 doi: 10.1186/s13024-022-00516-0
Rohn, T. T. & Moore, Z. D. Nuclear localization of apolipoprotein E4: a new trick for an old protein. Int. J. Neurol. Neurother. 4, 067 (2017).
pubmed: 29264400 pmcid: 5734658 doi: 10.23937/2378-3001/1410067
Theendakara, V. et al. Direct transcriptional effects of apolipoprotein E. J. Neurosci. 36, 685–700 (2016).
pubmed: 26791201 pmcid: 4719010 doi: 10.1523/JNEUROSCI.3562-15.2016
Hollingworth, P. et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat. Genet. 43, 429–435 (2011).
pubmed: 21460840 pmcid: 3084173 doi: 10.1038/ng.803
Pimenova, A. A. et al. Alzheimer’s-associated PU.1 expression levels regulate microglial inflammatory response. Neurobiol. Dis. 148, 105217 (2021).
pubmed: 33301878 doi: 10.1016/j.nbd.2020.105217
Gosselin, D. et al. An environment-dependent transcriptional network specifies human microglia identity. Science 356, eaal3222 (2017).
pubmed: 28546318 pmcid: 5858585 doi: 10.1126/science.aal3222
Liddelow, S. A. et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541, 481–487 (2017).
pubmed: 28099414 pmcid: 5404890 doi: 10.1038/nature21029
Katsouri, L. et al. Ablation of reactive astrocytes exacerbates disease pathology in a model of Alzheimer’s disease. Glia 68, 1017–1030 (2020).
pubmed: 31799735 doi: 10.1002/glia.23759
Boza-Serrano, A. et al. Galectin-3, a novel endogenous TREM2 ligand, detrimentally regulates inflammatory response in Alzheimer’s disease. Acta Neuropathol. 138, 251–273 (2019).
pubmed: 31006066 pmcid: 6660511 doi: 10.1007/s00401-019-02013-z
Tao, C. C. et al. Galectin-3 promotes Aβ oligomerization and Aβ toxicity in a mouse model of Alzheimer’s disease. Cell Death Differ. 27, 192–209 (2020).
pubmed: 31127200 doi: 10.1038/s41418-019-0348-z
Mabuchi, F. et al. The apolipoprotein E gene polymorphism is associated with open angle glaucoma in the Japanese population. Mol. Vis. 11, 609–612 (2005).
pubmed: 16110302
Lam, C. Y. et al. Association of apolipoprotein E polymorphisms with normal tension glaucoma in a Chinese population. J. Glaucoma 15, 218–222 (2006).
pubmed: 16778644 doi: 10.1097/01.ijg.0000212217.19804.a7
Margeta, M. A. et al. Association of APOE with primary open-angle glaucoma suggests a protective effect for APOE ε4. Invest. Ophthalmol. Vis. Sci. 61, 3 (2020).
pubmed: 32614373 pmcid: 7425753 doi: 10.1167/iovs.61.8.3
Tesseur, I. et al. Deficiency in neuronal TGF-β signaling promotes neurodegeneration and Alzheimer’s pathology. J. Clin. Invest. 116, 3060–3069 (2006).
pubmed: 17080199 pmcid: 1626127 doi: 10.1172/JCI27341
Wyss-Coray, T. et al. Amyloidogenic role of cytokine TGF-β1 in transgenic mice and in Alzheimer’s disease. Nature 389, 603–606 (1997).
pubmed: 9335500 doi: 10.1038/39321
Kandasamy, M. et al. TGF-β signaling: a therapeutic target to reinstate regenerative plasticity in vascular dementia? Aging Dis. 11, 828–850 (2020).
pubmed: 32765949 pmcid: 7390515 doi: 10.14336/AD.2020.0222
Yin, Z. et al. Identification of a protective microglial state mediated by miR-155 and interferon-λ signaling in a mouse model of Alzheimer’s disease. Nat. Neurosci. 26, 1196–1207 (2023).
pubmed: 37291336 doi: 10.1038/s41593-023-01355-y
Lund, H. et al. Fatal demyelinating disease is induced by monocyte-derived macrophages in the absence of TGF-β signaling. Nat. Immunol. https://doi.org/10.1038/s41590-018-0091-5 (2018).
Kaiser, T. & Feng, G. Tmem119-EGFP and Tmem119-CreERT2 transgenic mice for labeling and manipulating microglia. eNeuro 6, ENEURO.0448-18.2019 (2019).
Wang, J. W. et al. Influence of SHIP on the NK repertoire and allogeneic bone marrow transplantation. Science 295, 2094–2097 (2002).
pubmed: 11896280 doi: 10.1126/science.1068438
Ju, W. et al. Deletion of Smad2 in mouse liver reveals novel functions in hepatocyte growth and differentiation. Mol. Cell. Biol. 26, 654–667 (2006).
pubmed: 16382155 pmcid: 1346892 doi: 10.1128/MCB.26.2.654-667.2006
Li, Q. et al. Redundant roles of SMAD2 and SMAD3 in ovarian granulosa cells in vivo. Mol. Cell. Biol. 28, 7001–7011 (2008).
pubmed: 18809571 pmcid: 2593383 doi: 10.1128/MCB.00732-08
Huynh, T. V. et al. Lack of hepatic APOE does not influence early Aβ deposition: observations from a new APOE knock-in model. Mol. Neurodegener. 14, 37 (2019).
pubmed: 31623648 pmcid: 6796484 doi: 10.1186/s13024-019-0337-1
Sullivan, P. M. et al. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J. Biol. Chem. 272, 17972–17980 (1997).
pubmed: 9218423 doi: 10.1074/jbc.272.29.17972
Knouff, C. et al. Apo E structure determines VLDL clearance and atherosclerosis risk in mice. J. Clin. Invest. 103, 1579–1586 (1999).
pubmed: 10359567 pmcid: 408371 doi: 10.1172/JCI6172
Iwasaki, H. et al. Distinctive and indispensable roles of PU.1 in maintenance of hematopoietic stem cells and their differentiation. Blood 106, 1590–1600 (2005).
pubmed: 15914556 pmcid: 1895212 doi: 10.1182/blood-2005-03-0860
Proctor, J. M., Zang, K., Wang, D., Wang, R. & Reichardt, L. F. Vascular development of the brain requires β
pubmed: 16251442 pmcid: 2849654 doi: 10.1523/JNEUROSCI.3467-05.2005
Zhao, X. F. et al. Targeting microglia using Cx3cr1-Cre lines: revisiting the specificity. eNeuro 6, ENEURO.0114-19.2019 (2019).
Sanmarco, L. M. et al. Gut-licensed IFNλ
pubmed: 33408417 pmcid: 8039910 doi: 10.1038/s41586-020-03116-4
Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573–3587 (2021).
pubmed: 34062119 pmcid: 8238499 doi: 10.1016/j.cell.2021.04.048
Ianevski, A., Giri, A. K. & Aittokallio, T. Fully-automated and ultra-fast cell-type identification using specific marker combinations from single-cell transcriptomic data. Nat. Commun. 13, 1246 (2022).
pubmed: 35273156 pmcid: 8913782 doi: 10.1038/s41467-022-28803-w
Picelli, S. et al. Smart-seq2 for sensitive full-length transcriptome profiling in single cells. Nat. Methods 10, 1096–1098 (2013).
pubmed: 24056875 doi: 10.1038/nmeth.2639
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
pubmed: 25516281 pmcid: 4302049 doi: 10.1186/s13059-014-0550-8
Mootha, V. K. et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267–273 (2003).
pubmed: 12808457 doi: 10.1038/ng1180
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
pubmed: 16199517 pmcid: 1239896 doi: 10.1073/pnas.0506580102
Browaeys, R., Saelens, W. & Saeys, Y. NicheNet: modeling intercellular communication by linking ligands to target genes. Nat. Methods 17, 159–162 (2020).
pubmed: 31819264 doi: 10.1038/s41592-019-0667-5
Gu, Z., Gu, L., Eils, R., Schlesner, M. & Brors, B. circlize implements and enhances circular visualization in R. Bioinformatics 30, 2811–2812 (2014).
pubmed: 24930139 doi: 10.1093/bioinformatics/btu393
Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357–359 (2012).
pubmed: 22388286 pmcid: 3322381 doi: 10.1038/nmeth.1923
Tarasov, A., Vilella, A. J., Cuppen, E., Nijman, I. J. & Prins, P. Sambamba: fast processing of NGS alignment formats. Bioinformatics 31, 2032–2034 (2015).
pubmed: 25697820 pmcid: 4765878 doi: 10.1093/bioinformatics/btv098
Li, H. et al. The sequence alignment/map format and SAMtools. Bioinformatics 25, 2078–2079 (2009).
pubmed: 19505943 pmcid: 2723002 doi: 10.1093/bioinformatics/btp352
Ramirez, F., Dundar, F., Diehl, S., Gruning, B. A. & Manke, T. deepTools: a flexible platform for exploring deep-sequencing data. Nucleic Acids Res. 42, W187–W191 (2014).
pubmed: 24799436 pmcid: 4086134 doi: 10.1093/nar/gku365
Zhang, Y. et al. Model-based analysis of ChIP–seq (MACS). Genome Biol. 9, R137 (2008).
pubmed: 18798982 pmcid: 2592715 doi: 10.1186/gb-2008-9-9-r137
Bero, A. W. et al. Bidirectional relationship between functional connectivity and amyloid-β deposition in mouse brain. J. Neurosci. 32, 4334–4340 (2012).
pubmed: 22457485 pmcid: 3326343 doi: 10.1523/JNEUROSCI.5845-11.2012

Auteurs

Zhuoran Yin (Z)

Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA.

Neta Rosenzweig (N)

Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Kilian L Kleemann (KL)

Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
School of Computing, University of Portsmouth, Portsmouth, UK.

Xiaoming Zhang (X)

Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Wesley Brandão (W)

Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Milica A Margeta (MA)

Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA.

Caitlin Schroeder (C)

Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Kisha N Sivanathan (KN)

Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Evergrande Center for Immunologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Sebastian Silveira (S)

Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Christian Gauthier (C)

Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Dania Mallah (D)

Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Kristen M Pitts (KM)

Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA.

Ana Durao (A)

Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Shawn Herron (S)

Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.

Hannah Shorey (H)

Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Yiran Cheng (Y)

Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Jen-Li Barry (JL)

Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Rajesh K Krishnan (RK)

Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Evergrande Center for Immunologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Sam Wakelin (S)

Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Jared Rhee (J)

Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Anthony Yung (A)

Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Michael Aronchik (M)

Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Chao Wang (C)

Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.
Institute for Brain Science and Disease, Chongqing Medical University, Chongqing, China.

Nimansha Jain (N)

Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.

Xin Bao (X)

Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.

Emma Gerrits (E)

Department of Biomedical Sciences of Cells & Systems, Section Molecular Neurobiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

Nieske Brouwer (N)

Department of Biomedical Sciences of Cells & Systems, Section Molecular Neurobiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

Amy Deik (A)

Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Daniel G Tenen (DG)

Harvard Stem Cell Institute, Harvard Medical School, Boston, MA, USA.
Cancer Science Institute, National University of Singapore, Singapore, Singapore.

Tsuneya Ikezu (T)

Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.
Department of Neuroscience, Mayo Clinic Florida, Jacksonville, FL, USA.

Nicolas G Santander (NG)

Department of Pediatrics, University of California, San Francisco, San Francisco, CA, USA.
Instituto de Ciencias de la Salud, Universidad de O´Higgins, Rancagua, Chile.

Gabriel L McKinsey (GL)

Department of Pediatrics, University of California, San Francisco, San Francisco, CA, USA.

Caroline Baufeld (C)

Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Dean Sheppard (D)

Department of Medicine, Cardiovascular Research Center, University of California, San Francisco, San Francisco, CA, USA.

Susanne Krasemann (S)

Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Institute of Neuropathology, University Medical Center Hamburg-Eppendorf UKE, Hamburg, Germany.

Roni Nowarski (R)

Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Evergrande Center for Immunologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Bart J L Eggen (BJL)

Department of Biomedical Sciences of Cells & Systems, Section Molecular Neurobiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

Clary Clish (C)

Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Rudolph E Tanzi (RE)

Genetics and Aging Research Unit, Massachusetts General Hospital, Boston, MA, USA.

Charlotte Madore (C)

Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Laboratoire NutriNeuro, UMR1286, INRAE, Bordeaux INP, University of Bordeaux, Bordeaux, France.

Thomas D Arnold (TD)

Department of Pediatrics, University of California, San Francisco, San Francisco, CA, USA.

David M Holtzman (DM)

Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.

Oleg Butovsky (O)

Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. obutovsky@bwh.harvard.edu.
Evergrande Center for Immunologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. obutovsky@bwh.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH